Background: Oncolytic viruses (OV) are encouraging new immunotherapies for cancer. OVs induce
immunogenic cell death (ICD) and activate antitumour immunity. However, clinical use
has been limited to intratumoural delivery as a result of inadequate tumour targeting
following systemic injection, strong anti-viral host immune responses and sequestration
by the liver and spleen.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
A8
Identification
Copyright
© 2018 Published by Elsevier Inc.
